Charles River Laboratories has revealed plans to open Charles River Accelerator and Development Lab (CRADL) locations in Seattle and Philadelphia, expanding the company’s contract vivarium space for the biopharmaceutical industry.
CRADL Seattle is opening this September as Charles River’s most recent investment in Seattle, providing flexible vivarium space and on-demand in vivo study support services. CRADL’s first Seattle facility opened in 2021, in response to the city’s growing position as a key life sciences hub with significant start-up and entrepreneurial growth.
In October, CRADL Philadelphia will open in uCity Square to support Philadelphia’s growth as a life sciences biohub. Philadelphia has established itself as a leader in cell therapy, gene therapy, and gene editing, with a high number of gene therapy development companies developing in the Greater Philadelphia region.
With the addition of these two new sites, the company says the CRADL Vivarium Network operates 32 vivaria in key biohubs, including Massachusetts, California, Washington, Shanghai, Chengdu, London, Illinois, and now Pennsylvania.
“Both Seattle and Philadelphia are emerging as cities with significant biopharmaceutical communities. CRADL’s unique offering of contract vivarium space combined with Charles River’s extensive preclinical network, supports clients in starting projects quickly, without the costly burden of building infrastructure,” said Colin Dunn, Corporate Senior Vice President, Global Research Models & Services, Charles River.
Edited by: Diana Spencer, Senior Digital Content Editor, Drug Discovery World
